Dr Patrick Brown speaks to ecancer at the ASH 2019 meeting in Orlando about a randomised phase 3 trial, reported by the Children's Oncology Group, of blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse of B-ALL in children and adolescents.
Patients between the ages of 1-30 were enrolled and after the first month of chemotherapy were randomised to either receive more chemotherapy or blinatumomab, before then going onto bone marrow transplant.
Dr Brown reports that the experimental arm of blinatumomab showed around a 20% improvement in cure rates, establishing a new standard of care for these patients who have generally had a poor cure rate.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Watch the press conference here.
Read more about the study here.